A Phase 3 interventional study of Odevixibat in Biliary Atresia, sponsored by Albireo, an Ipsen Company. Active, not recruiting at 30 sites in 14 countries. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Albireo, an Ipsen Company (part of Ipsen) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Biliary Atresia with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Biliary Atresia · United States.
Among the 22 studies in Biliary Atresia with a site in United States, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 3, and was the 18th registered.
78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.
Browse Biliary Atresia studies →8 of the 22 studies in Biliary Atresia with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 2 wk–4 mo · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0 days–3 mo
Holterman, Ai-Xuan, M.D. · Sites in United States, Pakistan, Vietnam
Ages 14 days–180 days
University of Pittsburgh · Sites in United States
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 3
First in 2000; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 45 across 43 interventional studies indexed under Biliary Atresia.
Median enrollment 53 across the 14 interventional studies, 776 across the 8 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Albireo, an Ipsen Company, one of the names counted as Ipsen. Under that name alone:
Albireo, an Ipsen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.
Ipsen has 2 studies filed under Biliary Atresia — fewer than ten, so there is no comparison to draw.
1 of the studies in Biliary Atresia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07250854University of Alabama at BirminghamThe Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Biliary Atresia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia
This is a Phase 3, multi-center, open-label extension study to evaluate the long-term efficacy and safety of odevixibat in patients with Biliary Atresia (BA). Patients who completed treatment in the A4250-011 BOLD study and meet eligibility criteria for Study A4250-016 (BOLD-EXT) can participate. The duration of the treatment period is 104 weeks, followed by a 4-week Safety Follow-up Period. Patients who wish to continue receiving odevixibat after 104 weeks can remain on treatment in the optional extension period (OEP).
Up to 180 patients will be enrolled at approximately 70 sites in the North America, Europe, the Middle East and Asia-Pacific.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsules for oral administration once daily for 104 weeks.
Drug: Odevixibat
Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
Also known as: A4250
Proportion of patients who are alive and have not undergone liver transplant
Time frame: From baseline to Week 104
Change in aspartate aminotransferase (AST) to platelet ratio index (APRI) score
The APRI (aspartate aminotransferase to platelet ratio index) score estimates the severity of liver fibrosis. A higher score indicates a greater amount of scarring (fibrosis) in the liver. * A score ≤ 0.5 indicates a low likelihood of fibrosis * A score ≥ 1.5 indicates a higher probability of fibrosis
Time frame: From baseline to Week 104
Change in Fibrosis-4 (Fib-4) score
The Fib-4 score provides an estimate of the amount of scarring (fibrosis) in the liver. A higher score indicates a greater amount of scarring in the liver. * A score \< 1.45 indicates a low likelihood of fibrosis * A score \> 3.25 indicates a higher probability of fibrosis
Time frame: From baseline to Week 104
Change in serum bile acids
Time frame: From Baseline to Weeks 26, 52, 78, and 104
Change in height
Time frame: From Baseline to Weeks 26, 52, 78 and 104
Change in weight
Time frame: From Baseline to Weeks 26, 52, 78 and 104
Change in mid-arm circumference
Measure of growth
Time frame: From Baseline to Weeks 26, 52, 78 and 104
Time to onset of any sentinel events
Time frame: From Baseline to Week 104
Change in pediatric end-stage liver disease (PELD) score
The PELD (pediatric end-stage liver disease) score is a measure of disease severity. PELD scores can range from a negative value (such as -10) to high numbers (such as 45). A higher score indicates more severe disease.
Time frame: From Baseline to Weeks 26, 52, 78 and 104
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Oct 2026, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Odevixibat